BioMarin Pharmaceutical (BMRN) earnings

Earnings (net income) · fiscal 2025
$348.90M

BioMarin Pharmaceutical (BMRN) reported net income of $348.90M in fiscal 2025 (the year ended December 31, 2025). That is 18.3% lower than the $426.86M of fiscal 2024. Figures as of 18 Nov 2026, 06:38 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Earnings (net income), fiscal 2025
$348.90M
Change on fiscal 2024
−18.3%
Growth, 5 years
−16.4% a year
Highest on record
$854.03Mfiscal 2020
Lowest on record
-$630.21Mfiscal 2016
Fiscal years on record
182008–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

BioMarin Pharmaceutical earnings, in more detail

Over the five fiscal years to 2025 net income shrank at a compound 16.4% a year. Across the 18 fiscal years on record (2008–2025), the highest was $854.03M in fiscal 2020 and the lowest -$630.21M in fiscal 2016.

History · 18 fiscal years

Earnings (net income) by fiscal year

BioMarin Pharmaceutical earnings, year by year

BioMarin Pharmaceutical (BMRN) earnings by fiscal year
Fiscal yearEarnings (net income)ChangeYear ended
2025$348.90M 18.3% down
2024$426.86M 154.6% up
2023$167.65M 18.4% up
2022$141.56M—
2021-$64.08M 107.5% down
2020$854.03M—
2019-$23.85M—
2018-$77.21M—
2017-$117.04M—
2016-$630.21M—
2015-$171.80M—
2014-$133.97M—
2013-$176.35M—
2012-$114.35M—
2011-$53.84M 126.2% down
2010$205.82M—
2009-$488.00K 101.6% down
2008$30.83M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement.

How to read it

Compare it across years rather than in isolation — one-off gains and write-downs can swing a single year a long way.

Earnings (net income) at health care companies of similar size

Earnings (net income) of BioMarin Pharmaceutical and comparable companies
CompanyEarnings (net income)Fiscal year
Universal Health Services UHS$1.49B2025
Repligen RGEN$48.89M2025
Bio-Techne TECH$181.86M2026
BioMarin Pharmaceutical BMRN$348.90M2025
Avantor AVTR-$530.20M2025
Ensign Group ENSG$343.97M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on BMRN

BioMarin Pharmaceutical, figure by figure

BioMarin Pharmaceutical (BMRN) overview: price, valuation and scorecardAll health care companies by market value

BioMarin Pharmaceutical earnings: questions and answers

What is BioMarin Pharmaceutical's net income?

BioMarin Pharmaceutical (BMRN) reported net income of $348.90M in fiscal 2025 (the year ended December 31, 2025). That is 18.3% lower than the $426.86M of fiscal 2024.

What is the growth rate of BioMarin Pharmaceutical's net income?

Over the five fiscal years to 2025 net income shrank at a compound 16.4% a year.

What are the highest and lowest net income figures on record for BioMarin Pharmaceutical?

Across the 18 fiscal years on record (2008–2025), the highest was $854.03M in fiscal 2020 and the lowest -$630.21M in fiscal 2016.

How is BioMarin Pharmaceutical's net income calculated?

Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “BioMarin Pharmaceutical (BMRN) earnings”, data as of 18 November 2026. https://funkfolio.com/stock/BMRN/earnings

Underlying data: the company's filings with the SEC and Yahoo Finance.